Translation and Implementation of the Dutch VVAS Score in Clinical Practice

Sponsor

Universitair Ziekenhuis Brussel (Other)

Overall Status

Not yet recruiting

CT.gov ID

NCT06017466

Collaborator

(none)

Enrollment

Arm

Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

The aim of this study is to translate and introduce a cross-cultural adaptation of The Visual Vertigo Analogue Scale (VVAS). E. Dannenbaum et al developed the VVAS in order to diagnose visual vertigo (VV). VV is dizziness caused by visual stimuli such as scrolling through a computer screen or walking through crowds of people or supermarket aisles.

Condition or Disease	Intervention/Treatment	Phase
Vertigo	Diagnostic Test: Visual Vertigo Analogue Scale (VVAS)	N/A

Detailed Description

The Visual Vertigo Analogue Scale (VVAS) was developed by E. Dannenbaum et al in 2011 to diagnose visual vertigo. It is a nine-item analogue scale in which the subjects can rate their symptoms' intensity. The symptoms can be categorized as None (0), Mild (0.1-40), Moderate (40.01-70), or Severe (70.01-100). The VVAS is already available in English and French but a Dutch version does not yet exist. In this study, we would like to translate and introduce a cross-cultural adaptation of the VVAS into Dutch for use with vestibular patients in Belgium.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

10 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Intervention Model Description:

This will be a prospective interventional study with the Dutch VVAS questionnaire as interventional product.This will be a prospective interventional study with the Dutch VVAS questionnaire as interventional product.

Masking:

None (Open Label)

Primary Purpose:

Device Feasibility

Official Title:

Translation and Implementation of the Dutch VVAS Score in Clinical Practice

Anticipated Study Start Date :

Oct 1, 2023

Anticipated Primary Completion Date :

Jan 1, 2024

Anticipated Study Completion Date :

Mar 1, 2024

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Chronic Vertigo Chronic vertigo patients can be divided into three groups. The first pathway is episodic vertigo (caused by e.g. migraine, Ménière's disease, benign paroxysmal positional vertigo (BPPV)) progressively leading to chronic dizziness. The second pathway is initiated by a single attack of vertigo (e.g. neuritis vestibularis) with some initial recovery but later on residual symptoms. The third pathway is the presence of chronic, slowly progressive, continuous, or unchanging symptoms (e.g. bilateral vestibular failure, CNS disorders). All patient with chronic vertigo (see above) will included.	Diagnostic Test: Visual Vertigo Analogue Scale (VVAS) The Visual Vertigo Analogue Scale (VVAS) was developed by E. Dannenbaum et al in 2011 to diagnose visual vertigo. It is a nine-item analogue scale in which the subjects can rated the intensity of their symptoms. The symptoms can be categorized as None (0), Mild (0.1-40), Moderate (40.01-70) or Severe (70.01-100). The VVAS is already available in English and French but a Dutch version does not yet exist.

Arm

Intervention/Treatment

Experimental: Chronic Vertigo

Chronic vertigo patients can be divided into three groups. The first pathway is episodic vertigo (caused by e.g. migraine, Ménière's disease, benign paroxysmal positional vertigo (BPPV)) progressively leading to chronic dizziness. The second pathway is initiated by a single attack of vertigo (e.g. neuritis vestibularis) with some initial recovery but later on residual symptoms. The third pathway is the presence of chronic, slowly progressive, continuous, or unchanging symptoms (e.g. bilateral vestibular failure, CNS disorders). All patient with chronic vertigo (see above) will included.

Diagnostic Test: Visual Vertigo Analogue Scale (VVAS)

The Visual Vertigo Analogue Scale (VVAS) was developed by E. Dannenbaum et al in 2011 to diagnose visual vertigo. It is a nine-item analogue scale in which the subjects can rated the intensity of their symptoms. The symptoms can be categorized as None (0), Mild (0.1-40), Moderate (40.01-70) or Severe (70.01-100). The VVAS is already available in English and French but a Dutch version does not yet exist.

Outcome Measures

Primary Outcome Measures

vertigo symptoms assessed by the visual analogue scale [1 year]
Unit of measurement: score from 1 to 10 measurement tool: VVAS questionnaire

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 75 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

All patient with chronic vertigo (>3 years) will included
Interpretation of the VVAS is be possible
18-75 year

Exclusion Criteria:

Unable to read Dutch
Single episode of vertigo
75 year
Minors
When no interpretation of the VVAS is possible (e.g. too young, dementia)

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

Universitair Ziekenhuis Brussel

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

Universitair Ziekenhuis Brussel

ClinicalTrials.gov Identifier:

NCT06017466

Other Study ID Numbers:

22493VVAS

First Posted:

Aug 30, 2023

Last Update Posted:

Aug 30, 2023

Last Verified:

Dec 1, 2022

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Keywords provided by Universitair Ziekenhuis Brussel

Vertigo

Epidemiology

Visually Induced Dizziness

Chronic Vertigo

Additional relevant MeSH terms:

Vertigo

Dizziness

Study Results

No Results Posted as of Aug 30, 2023